Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the ...

UiPath Inc. (NYSE: PATH) was recently added to the S&P MidCap 400 index, replacing Synovus Financial Corp., reflecting the automation company's increased scale and market presence. This index ...

What To Know: After the market close on Tuesday, S&P Dow Jones Indices announced that agentic automation company UiPath will replace Synovus Financial Corp (NYSE: SNV) in the S&P MidCap 400, effective ...

You can use Path Actions to engage with the people you meet throughout Orsterra. This enters you into a negotiation with a chance to fail based on the relevant stats you possess. Path Actions are a ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Executing a new strategy nearly always involves acquiring new resources and capabilities. Since firms can’t possibly get everything they need through internal development, it seems reasonable in ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

There are many reasons why you may see the warning message: Pathway cannot be recreated. This page will help you determine if further action is required. Reasons why my Pathway cannot be recreated in ...

Adoptive cell therapy (ACT) is a treatment that uses a cancer patient's own T lymphocytes with anti-tumour activity, expanded in vitro and reinfused into the patient with cancer. ACT using autologous ...

J. William Carpenter is an economist who writes financial topics. He is an author of published works for higher education and business clients. Dr. JeFreda R. Brown is a financial consultant, ...